What were the key takeaways from AngioDynamics’s earnings call?

What were the key takeaways from AngioDynamics's earnings call?

What is AngioDynamics's latest dividend and current dividend yield?

What is AngioDynamics's gross profit margin?

What is the revenue and EPS growth rate for AngioDynamics year over year?

What is the market's earnings forecast for AngioDynamics next quarter?

What guidance did AngioDynamics's management provide for the next earnings period?

What factors drove the changes in AngioDynamics's revenue and profit?

- **12.2% Revenue Growth**: Med Tech segment up 26.1% to $35.3 million, driven by Auryon (+20.1%), AlphaVac (+52.3%), and NanoKnife (+26.7%).
- **Gross Margin Expansion**: 55.3% (up 90 bps) despite $1.7M tariffs, with operational efficiency gains.
- **Updated Guidance**: FY26 revenue raised to $308-313M, Med Tech +14-16%, and EBITDA guidance to $6-10M.
- **Sales Force Expansion**: 25% increase in Mechanical Thrombectomy reps to 50, targeting BTK and coronary market expansion.
- **CPT Code Impact**: NanoKnife prostate treatment CPT code effective Q3, with AARP ad campaign driving patient awareness.
- **Clinical Momentum**: AMBITION BTK study enrollment on track, supporting Auryon's BTK leadership.


**【CEO Summary Section】**
- **Revenue Growth**: Q1 revenue increased 12.2% to $75.3 million, driven by a 26.1% surge in the Med Tech segment to $35.3 million and 2.3% growth in the Med Device segment to $40.4 million.
- **Auryon Performance**: Auryon revenue rose 20.1% to $16.5 million, marking 17 consecutive quarters of double-digit growth, with international expansion contributing $500,000.
- **Mechanical Thrombectomy**: Combined AngioVac and AlphaVac revenue jumped 41.2% to $11.3 million, with AlphaVac up 52.3%.
- **NanoKnife Expansion**: Revenue climbed 26.7% to $6.4 million, driven by the expanded prostate indication and upcoming CPT code in Q3.
- **Gross Margin**: Improved 90 basis points to 55.3%, despite $1.7 million in tariffs, with operational efficiency gains.
- **Guidance Update**: Full-year revenue raised to $308-$313 million (5-7% growth), Med Tech up 14-16%, and adjusted EBITDA guidance increased to $6-10 million.

**【CFO Financial Commentary】**
- **Segment Breakdown**: Med Tech now 47% of total revenue vs. 41% last year, reflecting strategic shift. Med Tech CAGR 25% since 2020.
- **Tariff Impact**: Expect $4-6 million annually, with Q1 at $1.7 million. Gross margin initiatives ahead of schedule.
- **Operating Efficiency**: Total expenses at 69.4% of sales vs. 74% last year, with R&D at 8.5% and SG&A at 53.7%.
- **Cash Flow**: Q1 cash utilization $38.8 million vs. $55.9 million last year, targeting FY26 cash flow positive.

**【Q&A Highlights】**
- **Sales Force Expansion**: Mechanical Thrombectomy team expanded 25% to 50 reps, mirroring Auryon's successful 5-year build-out.
- **NanoKnife Reimbursement**: CPT code effective Jan 2026, with urology adoption accelerating post-campaign launch.
- **Clinical Trials**: AMBITION BTK study enrollment on track, with Auryon's unique design driving BTK market share growth.
- **Revenue Mix**: 47% Med Tech vs. 41% last year, with pricing and utilization driving mechanical thrombectomy growth.


AngioDynamics, Inc. (ANGO) Q1 2026 Earnings Call Transcript

- **Revenue Growth**: FY 2025 total revenue $292.7M (+8.1%), Med Tech segment doubles as % of total (43% vs. 22% 5 years ago). Q4 Med Tech 45% of revenue.
- **Key Product Momentum**: Auryon 16 straight quarters of double-digit growth, AlphaVac 59.5% FY 2025 growth, NanoKnife prostate procedures 81% Q4.
- **Strategic Wins**: Europe Auryon revenue $1M Q4, NanoKnife CPT codes for prostate and pancreas effective 2026/2027.
- **Financial Targets**: FY 2026 revenue $305-310M, Med Tech +12-15%, gross margin 53.5-55.5%, cash flow positive.
- **Risks**: Tariffs FY 2026 impact $4-6M, but no material impact on growth trajectory. Manufacturing transition to save $15M by FY 2027.


**【CEO Opening Remarks】**
- **Q4 2025 Performance**: Total revenue of $80.2M (+12.7% YoY), driven by Med Tech (+22%) and Med Device (+6.2%). Adjusted EBITDA of $3.4M and $16.2M free cash flow.
- **Med Tech Growth**: Auryon revenue $15.6M (+19.7%), mechanical thrombectomy (AngioVac/AlphaVac) up 44.7%, NanoKnife $7.2M (-2.5% due to capital sales decline).
- **Strategic Focus**: Transition to high-growth Med Tech markets (5-year CAGR 25%), with Auryon, thrombectomy, and NanoKnife as key platforms. International expansion (Europe Auryon revenue $1M Q4) and clinical trials (AMBITION BTK, RECOVER-AV) driving adoption.

**【CFO Financial Commentary】**
- **FY 2025 Results**: Revenue $292.7M (+8.1%), Med Tech $126.7M (+19.5%). Gross margin 53.9% (52.7% Q4), impacted by $1.6M tariffs. Adjusted EBITDA $7.6M vs. -$3.2M prior year.
- **FY 2026 Guidance**: Revenue $305-310M (+4-6%), Med Tech +12-15%, Med Device flat. Gross margin 53.5-55.5% (tariffs $4-6M). Adjusted EBITDA $3-8M, cash flow positive.
- **Tariff Impact**: FY 2026 impact $4-6M, manufacturing transition to save $15M by FY 2027.

**【Q&A Highlights】**
- **AlphaVac Blood Return**: Ancillary 510(k) product in regulatory discussions; no clinical trial needed. Sequential growth expected despite current ceiling without feature.
- **NanoKnife Reimbursement**: CPT I codes effective Jan 2026 for prostate and pancreas. Urology adoption accelerating; disposable sales growth 5.5% Q4.
- **Product Pipeline**: Auryon coronary application R&D, AlphaVac blood return version in development. No plans for acquisitions/divestitures; focused on executing current strategy.
- **Gross Margin Outlook**: Ex-tariffs, 55-56% FY 2026. Manufacturing transition benefits materializing in back half FY 2026.
- **Cash Flow**: Q1 FY 2026 cash use $20M, positive for full year. revolver ($25M) for working capital flexibility.


AngioDynamics, Inc. (ANGO) Q4 2025 Earnings Call Transcript

- **Revenue Growth**: Q3 FY2025 total revenue $72M (+9.2% YoY), Med Tech segment up 22.2%.
- **Star Performers**: Auryon (+17.3%), AlphaVac (+161.4%), AngioVac (+23.1%), NanoKnife probe (+16.2%).
- **Profitability**: Gross margin 54.0%, EBITDA $1.3M (vs. -$3.6M YoY).
- **Guidance Uptick**: FY2025 revenue $285-288M, Med Tech growth 14%-16%, EBITDA $4-5M.
- **Key Catalysts**: AngioVac/AlphaVac synergy, NanoKnife prostate reimbursement, Auryon EU expansion.

**【CEO Summary Section】**
- Total revenue for Q3 FY2025 was $72 million, up 9.2% YoY, driven by Med Tech segment growth (22.2%) and strong performance in Auryon, AlphaVac, and AngioVac.
- Med Tech revenue reached $31.3 million, accounting for 44% of total revenue, up from 39% YoY. Key highlights:
  - Auryon revenue: $13.9 million (+17.3% YoY), 15 consecutive quarters of double-digit growth.
  - AlphaVac revenue: $3 million (+161.4% YoY), sequential growth for 4th quarter.
  - AngioVac revenue: $6.8 million (+23.1% YoY), maintaining strong momentum.
- NanoKnife probe revenue grew 16.2% YoY, with prostate cases now >50% of total treatments post FDA expanded indication.
- Adjusted EBITDA improved to $1.3 million (vs. -$3.6 million YoY), with Q4 expected to be the strongest quarter of the year.

**【CFO Financial Commentary】**
- Gross margin expanded to 54.0% (vs. 51.1% YoY), driven by Med Tech mix and operational efficiency.
- R&D expense: $6.9 million (9.6% of sales), down 12.2% YoY due to clinical trial completion.
- SG&A: $36 million (50.0% of sales), stable vs. 51.9% YoY.
- Cash balance: $44.8 million, with Q4 expected to end at $55 million post $25M revolver close.
- Updated FY2025 guidance:
  - Revenue: $285-288 million (+5.3%-6.4% YoY)
  - Med Tech growth: 14%-16%
  - Gross margin: 53%-54%
  - Adjusted EBITDA: $4-5 million
  - Adjusted EPS: -$0.31 to -$0.34

**【Q&A Key Highlights】**
- **AngioVac & AlphaVac Synergy**: Q3 AngioVac revenue $6.8M (+23% YoY), AlphaVac sequential growth 20%. Commercial team expansion planned for FY2026.
- **NanoKnife Prostate Adoption**: FDA expanded indication in Dec 2024, CPT1 code effective Jan 2025. Reimbursement updates expected July 2025.
- **Auryon EU Launch**: CE mark in Q1, early Q4 revenue contributions expected with distributor support.
- **AMBITION BTK Trial**: Enrollment Q4 2025, targeting below-the-knee CLI patients to validate Auryon's clinical benefit.
- **Cash Flow Outlook**: FY2026 target: cash flow positive, supported by Med Tech growth and cost control.

AngioDynamics (ANGO)-2 Apr 25-2025 Q3 Earnings call transcript

- **Revenue Growth**: Q2 revenue up 9% YoY to $73M, with Med Tech segment leading at +25%.
- **Profitability Improving**: Adjusted EBITDA turns positive ($3.1M), operating cash flow $2.5M.
- **Key Product Wins**: 
  - AngioVac/AlphaVac mechanical thrombectomy up 46% YoY.
  - NanoKnife disposable revenue +23% YoY.
  - Auryon 14 straight quarters of double-digit growth.
- **Future Outlook**: FY2025 guidance for $282-288M revenue, $1-3M adjusted EBITDA.
- **Strategic Shifts**: 
  - $15M annualized savings from manufacturing transition by FY2027.
  - Expanding Med Tech to 43% of revenue (vs. 37.7% YoY).

**【CEO Opening Remarks】**
- Q2 FY2025 revenue: $73M (+9% YoY), driven by Med Tech segment (+25%) and U.S. Med Device (+2% YoY). 
- Adjusted EBITDA: $3.1M (vs. -$10K YoY), operating cash flow: $2.5M.
- Key product highlights:
  - Auryon: $13.7M (+22% YoY), 14 consecutive quarters of double-digit growth.
  - Mechanical thrombectomy (AngioVac + AlphaVac): $10.6M (+46% YoY), with AngioVac up 51% YoY.
  - NanoKnife: $6M (+5% YoY), disposable revenue +23% YoY.
- Full-year guidance: $282-288M revenue, +12-15% Med Tech growth, adjusted EBITDA $1-3M.

**【CFO Financial Details】**
- Gross margin: 54.7% (flat YoY), Med Tech gross margin 63.7% (up 120bps vs. AngioVac mix).
- R&D expense: $6.4M (8.8% of sales, down from 12.5% YoY).
- SG&A: $36M (49.3% of sales, stable YoY).
- Cash: $54.1M (vs. $55M prior quarter), targeting $60M by year-end.
- Manufacturing transition savings: $15M annualized by FY2027.

**【Q&A Key Takeaways】**
1. **Thrombectomy Growth**: 
 - AngioVac growth driven by expanded U.S. adoption; AlphaVac PE indication gaining traction post-APEX trial publication.
 - Synergies between products: AlphaVac sales open doors for AngioVac in new accounts.

2. **Auryon Strategy**: 
 - Shifting focus to hospital customers (now 35% of revenue) despite OBL market headwinds.
 - CE Mark for Europe enables limited launch in Q3, with full market release planned for FY2026.

3. **NanoKnife Momentum**: 
 - FDA clearance for prostate ablation, new CPT codes effective Jan 2026.
 - PRESERVE trial data shows 84% freedom from clinically significant cancer at 12 months.

4. **Competitive Positioning**: 
 - Med Tech segment now 43% of revenue (vs. 37.7% YoY), expanding addressable market to $10B+.
 - Manufacturing transition on track to reduce overhead costs by FY2027.

ANGO

ANGO fundamentals

Earnings Call

You can ask Aime